| [1] |
Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries[J]. CA Cancer J Clin, 2026, 76(4): DOI: 10.3322/caac.70090.
|
| [2] |
孙可欣, 李荔, 王少明, 等. 2024年中国分地区恶性肿瘤流行分析[J]. 中华肿瘤杂志, 2026, 48(3): 400-412. DOI: 10.3760/cma.j.cn112152-20260205-00079.
|
| [3] |
Li KX, Zhang A, Li XY, et al. Advances in clinical immunotherapy for gastric cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2): 188615. DOI: 10.1016/j.bbcan.2021.188615.
|
| [4] |
王羌成, 鲍军. Claudin18.2--胃癌治疗的新兴靶点中国临床研究[J]. 中国临床研究, 2024, 37(2): 171-176. DOI: 10.13429/j.cnki.cjcr.2024.02.002.
|
| [5] |
Zhang J, Dong R, Shen L. Evaluation and reflection on Claudin 18.2 targeting therapy in advanced gastric cancer[J]. Chin J Cancer Res, 2020, 32(2): 263-270. DOI: 10.21147/j.issn.1000-9604.2020.02.13.
|
| [6] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胃癌诊疗指南2025[M]. 北京: 人民卫生出版社, 2025.
|
| [7] |
WHO Classification of Tumours Editorial Board. WHO classification of tumours: digestive system tumours[M]. 5th ed. Vol 1. Geneva: International Agency for Research on Cancer, 2019. DOI: 10.1016/B978-92-832-4499-0.99999-7.
|
| [8] |
Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adeno-carcinoma: the randomized, phase 3 GLOW trial[J]. Nat Med, 2023, 29(8): 2133-2141. DOI: 10.1038/s41591-023-02465-7.
|
| [9] |
《胃癌Claudin18.2临床检测专家共识(2025版)》专家委员会. 胃癌Claudin18.2临床检测专家共识(2025版)[J]. 中华病理学杂志, 2025, 54(7): 718-725. DOI: 10.3760/cma.j.cn112151-20250408-00245.
|
| [10] |
Fassan M, Kuwata T, Matkowskyj KA, et al. Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach[J]. Mod Pathol, 2024, 37(11): 100589. DOI: 10.1016/j.modpat.2024.100589.
|
| [11] |
Lal-Nag M, Morin PJ. The claudins[J]. Genome Biol, 2009, 10(8): 235. DOI: 10.1186/gb-2009-10-8-235.
pmid: 19706201
|
| [12] |
Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet, 2023, 401(10389): 1655-1668. DOI: 10.1016/s0140-6736(23)00620-7.
pmid: 37068504
|
| [13] |
Hashimoto I, Oshima T. Claudins and gastric cancer: an overview[J]. Cancers (Basel), 2022, 14(2): 290. DOI: 10.3390/cancers14020290.
|
| [14] |
Liu JY, Yang HC, Yin DJ, et al. Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma[J]. Pathol Res Pract, 2022, 238: 154068. DOI: 10.1016/j.prp.2022.154068.
|
| [15] |
Kayikcioglu E, Yüceer RO, Cetin B, et al. Prognostic value of Claudin 18.2 expression in gastric adenocarcinoma[J]. World J Gastrointest Oncol, 2023, 15(2): 343-351. DOI: 10.4251/wjgo.v15.i2.343.
|
| [16] |
Dottermusch M, Krüger S, Behrens HM, et al. Expression of the potential therapeutic target Claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study[J]. Virchows Arch, 2019, 475(5): 563-571. DOI: 10.1007/s00428-019-02624-7.
|
| [17] |
Cao WJ, Xing HZ, Li YM, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy[J]. Biomark Res, 2022, 10(1): 38. DOI: 10.1186/s40364-022-00385-1.
pmid: 35642043
|
| [18] |
Nakayama I, Qi CS, Chen Y, et al. Claudin 18.2 as a novel therapeutic target[J]. Nat Rev Clin Oncol, 2024, 21(5): 354-369. DOI: 10.1038/s41571-024-00874-2.
pmid: 38503878
|
| [19] |
Arnold A, Daum S, von Winterfeld M, et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas[J]. Clin Transl Oncol, 2020, 22(12): 2357‑2363. DOI: 10.1007/s12094-020-02380-0.
|
| [20] |
Röcken C, Höhn AK, Neumann J, et al. Concordance of laboratory assays for Claudin 18.2 in gastric cancer tissue samples: independent proficiency testing and a descriptive non-interventional study[J]. Virchows Arch, 2025, 487(5): 1117-1125. DOI: 10.1007/s00428-025-04138-x.
|